DaVita HealthCare Partners Now Covered by Atlantic Securities (DVA)
Equities researchers at Atlantic Securities assumed coverage on shares of DaVita HealthCare Partners (NYSE:DVA) in a research report issued on Thursday, AnalystRatings.NET reports. The firm set an “overweight” rating on the stock.
Shares of DaVita HealthCare Partners (NYSE:DVA) opened at 57.36 on Thursday. DaVita HealthCare Partners has a 52-week low of $52.23 and a 52-week high of $65.665. The stock has a 50-day moving average of $56.47 and a 200-day moving average of $59.. The company has a market cap of $12.195 billion and a price-to-earnings ratio of 20.33.
DaVita HealthCare Partners (NYSE:DVA) last announced its earnings results on Tuesday, August 6th. The company reported $1.84 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.84. The company had revenue of $2.87 billion for the quarter, compared to the consensus estimate of $2.88 billion. During the same quarter in the previous year, the company posted $1.49 earnings per share. The company’s revenue for the quarter was up 50.1% on a year-over-year basis. On average, analysts predict that DaVita HealthCare Partners will post $3.78 earnings per share for the current fiscal year.
A number of other firms have also recently commented on DVA. Analysts at Piper Jaffray Cos. cut their price target on shares of DaVita HealthCare Partners from $135.00 to $132.00 in a research note to investors on Wednesday, August 7th. Separately, analysts at Zacks reiterated a “neutral” rating on shares of DaVita HealthCare Partners in a research note to investors on Wednesday, August 7th. They now have a $122.00 price target on the stock. Finally, analysts at RBC Capital downgraded shares of DaVita HealthCare Partners from an “outperform” rating to a “sector perform” rating in a research note to investors on Wednesday, August 7th. They now have a GBX 115 ($1.85) price target on the stock, down previously from GBX 127 ($2.04). One research analyst has rated the stock with a sell rating, five have given a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $126.00.
DaVita HealthCare Partners Inc, formerly DaVita Inc, is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (NYSE:DVA).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.